The most potent BBOX inhibitor identifiedwas Enarodustat (IC50 ∼ 0.10 μM; Table 1, entry iv), whichis approved for the treatment of CKD-associated anemia in Japan.58,62 Notably, Enarodustat manifested ∼5-fold more efficient BBOXinhibition in the SPE-MS inhibition assays than AR692B (IC50 ∼ 0.52 μM; Table 1, entry i), and >500-fold more efficient BBOX inhibitionthan clinically used Mildronate (IC50 > 50 μM; Table 1, entry ii). Here, BBOX1 is linked to anemia.